A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.

Trial Details

NCT ID
NCT06457503
Phase
PHASE4
Sponsor
Coherus Oncology, Inc.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Toripalimab
  • Cisplatin
  • Gemcitabine
  • Carboplatin
Locations (sample)
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Irvine, California, United States|33.66946,-117.82311
  • San Francisco, California, United States|37.77493,-122.41942
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Histological or cytological confirmation of recurrent/metastatic nasopharyngeal cancer with either EBV or non-EBV-associated cancer. The following …
  • EBER/EBV-negative (HPV+/-)
  • EBER/EBV-positive (HPV+/-)
  • Recurrent/metastatic (stage IV-B as defined by the International Union against Cancer \[UICC\] and American Joint Committee on Cancer \[AJCC\] stag…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →